Gain Therapeutics, Inc. GANX 深 滬
等待開盤 09-25 09:30:00 美东时间
1.74
-0.010
-0.57%
華盛通- 最 高1.785
- 今 開1.76
- 成交量 57.94万股
- 最 低 1.68
- 昨 收 1.75
- 總市值 5210.53万
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 1.93%
- 52周最低 1.41
- 委 比 11.95%
- 總股本 2994.56万
- 歷史最高 17.93
- 量 比 0.78
- 振 幅 6.00%
- 歷史最低 0.89
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Gain Therapeutics' Director of AI, Dr. Rinaldo Montalvão, will present at the WORLD BI DDIP 2025 conference in Barcelona on September 26. His talk, "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity," will focus on AI and automation in drug discovery. Gain Therapeutics specializes in developing next-generation allosteric therapies, with its lead candidate GT-02287 in Phase 1b trials for Parkinson's disease. The comp...
09-23 11:40
Gain Therapeutics Begins GT-02287 Phase 1b Extension Study Allowing Participants To Continue Treatment For Additional Nine Months
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing scheduleThe Phase 1b study enrolled 21 subjects and the last
09-18 19:45
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Gain Therapeutics announced that its Phase 1b clinical trial for GT-02287, a potential treatment for Parkinson's disease, has been extended by nine months for participants who completed the initial three-month study. The independent data monitoring committee (DMC) reviewed interim safety data and recommended continuing the study without changes. GT-02287, an orally administered, brain-penetrant small molecule, aims to restore lysosomal enzyme fun...
09-04 12:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Roth Capital Maintains Buy on Gain Therapeutics, Lowers Price Target to $6
Roth Capital analyst Boobalan Pachaiyappan maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $7 to $6.
08-14 01:14
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Gain Therapeutics announced that its management team will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biotechnology Conference from July 29 to 30, 2025. The fireside chat is scheduled for July 30 at 3:20pm ET. Gain is a clinical-stage biotech company focused on next-generation allosteric therapies, with its lead candidate, GT-02287, in a Phase 1b trial for Parkinson's disease. The company's Magellan platform ac...
07-24 12:53
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.
07-16 18:08
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Shares of Data Storage Corporation (NASDAQ:DTST) rose sharply in pre-market tra...
07-16 18:04
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
Gain Therapeutics announced the pricing of a public offering of 4.5 million shares of common stock and warrants to purchase 2.25 million shares, priced at $3.11 per set of securities. The company expects to raise approximately $7 million, excluding underwriting discounts. The offering is set to close on July 17 and the proceeds will be used for clinical development of its lead candidate GT-02287 for neurodegenerative diseases like GBA1 Parkinson’...
07-16 13:03
Gain Therapeutics announces proposed public offering
Gain Therapeutics (NASDAQ:GANX) announced on Tuesday that it is proposing to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. The com...
07-16 04:41
